Methyl 5-[(1S,2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]-3-thiophenecarboxylate | 1818257-78-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: Methyl 5-[(1S,2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]-3-thiophenecarboxylate
• 英文别名: methyl 5-[(1S,2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopropyl]thiophene-3-carboxylate
• CAS: 1818257-78-1
• 化学式: C₁₄H₁₉NO₄S
• 分子量: 297.37
• InChiKey: BUGKHVILZUOTDZ-UWVGGRQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• CYCLOPROPANAMINE COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150291577A1

  公开（公告）日：2015-10-15

  The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有赖氨酸特异性去甲基化酶-1抑制作用的化合物，可用作药物，例如预防或治疗精神分裂症、发育障碍，特别是智力障碍性疾病（例如自闭症谱系障碍、雷特综合征、唐氏综合征、歌舞伎综合征、脆性X综合征、Kleefstra综合征、神经纤维瘤病1型、Noonan综合征、结节性硬化）和神经退行性疾病（例如阿尔茨海默病、帕金森病、小脑萎缩性疾病（例如小脑纹状体苍白球变性症）和亨廷顿病）、癫痫（例如Dravet综合征）或药物依赖等。其中每个符号如本说明书中所定义的，或其盐的化合物。
• Cyclopropanamine compound and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10053456B2

  公开（公告）日：2018-08-21

  The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有赖氨酸特异性去甲基化酶-1 抑制作用的化合物，该化合物可用作药物，如精神分裂症、发育障碍，尤其是智力障碍疾病（如自闭症谱系障碍、雷特综合征、唐氏综合征、卡布基综合征、脆性 X 综合征、克莱夫斯特拉综合征、神经纤维瘤病 1 型、努南综合征、结节性硬化症）的预防或治疗药物、自闭症谱系障碍、雷特综合征、唐氏综合征、歌舞伎综合征、脆性 X 综合征、克莱夫斯特拉综合征、神经纤维瘤病 1 型、努南综合征、结节性硬化症）、神经退行性疾病（如阿尔茨海默病、帕金森病、脊髓小脑变性（如齿状突眼苍白肌萎缩症）和亨廷顿病）、癫痫（如德拉韦特综合征）或药物依赖等。由式（其中各符号如本说明书所定义）代表的化合物或其盐。
• US9487511B2
  申请人：——

  公开号：US9487511B2

  公开（公告）日：2016-11-08
• US9714241B2
  申请人：——

  公开号：US9714241B2

  公开（公告）日：2017-07-25
• US9718814B2
  申请人：——

  公开号：US9718814B2

  公开（公告）日：2017-08-01